Skip to main content

Advertisement

Table 1 Patient characteristics

From: High-dose thiotepa-related neurotoxicity and the role of tramadol in children

  Patients (N = 251)
Gender
 Boys 145 (58%)
 Girls 106 (43%)
Age (years; median [IQR]) 8 [5–15]
Race  
 Caucasian 186 (74%)
 African 40 (16%)
 Others 25 (10%)
Brain tumour 116 (46%)
 Medulloblastoma 71 (28%)
 PNETa 26 (10%)
 Pinealoblastoma 13 (5%)
 ATRTb 5 (2%)
 Malignant GCTc 1 (0.4%)
Other tumour site 135 (54%)
 Osteosarcoma 50 (20%)
 Neuroblastoma 26 (10%)
 Ewing tumor 23 (9%)
 Rhabdomyosarcoma 20 (8%)
 Other sarcoma 4 (2%)
 Nephroblastoma 4 (2%)
 Burkitt lymphoma 4 (2%)
 Hepatoblastoma 2 (1%)
 Desmoplastic tumour 2 (1%)
Neurological disorder at baselined 20 (8%)
History of seizure 13 (5%)
Thiotepa dose
 600 mg/m2 129 (51%)
 720 mg/m2 76 (30%)
 900 mg/m2 46 (18%)
Concomitant drugse
 Alizapride 94 (43%)
 Antibiotic 49 (22%)
 Antidepressant 7 (3%)
 Antipsychotic 40 (18%)
 Aprepitant 7 (3%)
 Benzodiazepine 43 (20%)
 Histamine H2-receptor antagonist 5 (2%)
 Proton Pump Inhibitor 7 (3%)
Analgesics 92 (42%)
 Simple analgesics 76 (35%)
 i.e. acetaminophen, nefopam  
 Weak opioids 53 (24%)
 i.e. tramadol, codeine, dextropropoxyphen  
 Strong opioids 9 (4%)
 i.e. morphine, pethidine  
  1. Data are numbers (%), unless otherwise stated
  2. aPrimitive NeuroEctodermal Tumour
  3. bAtypical Teratoid Rhabdoid Tumour
  4. cMalignant Germ Cell Tumour
  5. dData missing for one patient
  6. eData missing for 31 patients